<DOC>
	<DOC>NCT02343627</DOC>
	<brief_summary>This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.</brief_summary>
	<brief_title>Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail</brief_title>
	<detailed_description>This Phase IIa pilot multiple-dose study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Clinically diagnosed onychomycosis Presence of dermatophyte fungal infection with no current topical or systemic antifungal therapy Clinical diagnosis of mildtomoderate fungal infection of at least one toe involving 1050% of the nail area, without involvement of one of the lunular proximal regions Positive potassium hydroxide mount preparation Positive fungal culture for a dermatophyte Nail or anatomical abnormalities of the toe that may interfere with evaluations or dosing compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>